WST Earnings Date: Feb 11, 2027 (Estimated) — West Pharmaceutical Services, Inc.
NYSE · Healthcare · Medical Instruments & Supplies
Updated
When is WST's next earnings date?
West Pharmaceutical Services, Inc. (WST) is expected to report Q4 2026 earnings on Thursday, February 11, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.27 on revenue of $827.2M.
How did WST do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), West Pharmaceutical Services, Inc. posted EPS of $2.66 versus the $2.20 estimate, a beat of 20.9%. Revenue was $874.5M against a $827.1M estimate. The stock's 1-day post-earnings move was +3.2%.
How much does WST stock move after earnings?
WST beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.7% (up or down) in the day after earnings.
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
🤖 AI Earnings Analysis
West delivered a strong quarter, with revenue up 8.7% to $875M and EPS rising 20.3% to $2.66, beating estimates; it raised full-year sales and EPS guidance, reinforcing momentum in injectable-drug packaging.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 2.20 | 2.66 | +20.91% | $874.5M | ✅ Beat | +3.23% | — | — |
| 2026-07-23 | Q2 2026 | 2.08 | 2.37 | +13.94% | $872.3M | ✅ Beat | -0.82% | -5.78% | -1.23% |
| 2026-04-23 | Q1 2026 | 1.68 | 2.13 | +26.79% | $844.9M | ✅ Beat | +12.86% | +7.72% | +15.29% |
| 2026-02-12 | Q4 2025 | 1.83 | 2.04 | +11.48% | $805.0M | ✅ Beat | -1.03% | -0.94% | -4.34% |
| 2025-10-23 | Q3 2025 | 1.68 | 1.96 | +16.67% | $804.6M | ✅ Beat | +10.92% | +2.84% | -6.87% |
| 2025-04-24 | Q1 2025 | 1.23 | 1.45 | +17.89% | $698.0M | ✅ Beat | -3.48% | -3.06% | -4.35% |
| 2025-02-13 | Q4 2024 | 1.73 | 1.82 | +5.20% | $748.8M | ✅ Beat | -38.22% | -36.81% | -28.60% |
| 2024-10-24 | Q3 2024 | 1.50 | 1.85 | +23.33% | $746.9M | ✅ Beat | +15.43% | +9.28% | +12.09% |
Showing last 8 quarters.
Revenue by segment & region
By region
FY2025 · $3.07B total · annual
| Segment | Share | Revenue | YoY | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 43.3% | $1.33B | +8.0% | $814.7M | $975.6M | $1.20B | $1.29B |
| Other Europe Countries | 14.7% | $451.0M | +17.0% | $251.1M | $236.8M | $341.3M | $359.2M |
| GERMANY | 12.4% | $380.3M | +2.1% | $236.3M | $282.1M | $474.3M | $398.7M |
| Other Countries | 11.5% | $353.3M | +4.2% | $213.4M | $253.7M | $357.4M | $364.3M |
| IRELAND | 10.8% | $333.3M | +3.1% | $173.8M | $226.0M | $247.6M | $240.3M |
| FRANCE | 7.4% | $226.6M | -6.4% | $150.6M | $172.7M | $213.0M | $237.9M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.